BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29270848)

  • 1. Role of CT Density in PET/CT-Based Assessment of Lymphoma.
    Flechsig P; Walker C; Kratochwil C; König L; Iagura A; Moltz J; Holland-Letz T; Kauczor HU; Haberkorn U; Giesel FL
    Mol Imaging Biol; 2018 Aug; 20(4):641-649. PubMed ID: 29270848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.
    Flechsig P; Frank P; Kratochwil C; Antoch G; Rath D; Moltz J; Rieser M; Warth A; Kauczor HU; Schwartz LH; Haberkorn U; Giesel FL
    Mol Imaging Biol; 2017 Apr; 19(2):315-322. PubMed ID: 27539308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.
    Giesel FL; Schneider F; Kratochwil C; Rath D; Moltz J; Holland-Letz T; Kauczor HU; Schwartz LH; Haberkorn U; Flechsig P
    J Nucl Med; 2017 Feb; 58(2):282-287. PubMed ID: 27660141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.
    Flechsig P; Rastgoo R; Kratochwil C; Martin O; Holland-Letz T; Harms A; Kauczor HU; Haberkorn U; Giesel FL
    Mol Imaging Biol; 2018 Dec; 20(6):1044-1052. PubMed ID: 29679299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
    Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
    J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma.
    Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C
    Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
    Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of
    Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
    J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of
    Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
    Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of alteration in liver
    Salomon T; Nganoa C; Gac AC; Fruchart C; Damaj G; Aide N; Lasnon C
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):941-950. PubMed ID: 29279943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.